Company Overview - Dabo Medical's closing price on July 2 was 35.9 yuan, down 1.94%, with a rolling PE ratio of 37.33 times and a total market value of 14.863 billion yuan [1] - The company ranks 77th in the medical device industry, which has an average PE ratio of 51.29 times and a median of 37.02 times [1] Shareholder Information - As of March 31, 2025, Dabo Medical had 18,310 shareholders, an increase of 374 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Dabo Medical specializes in the production, research, and sales of high-value medical consumables, with key products including intramedullary nails, hollow nails, ordinary plates, locking plates, external fixators, bone needles, spinal fixation devices, and various joint prostheses [1] Financial Performance - In the first quarter of 2025, Dabo Medical reported revenue of 550 million yuan, a year-on-year increase of 28.80%, and a net profit of 103 million yuan, up 67.04%, with a gross profit margin of 69.64% [1] Industry Comparison - The PE ratios for Dabo Medical and its peers show significant variation, with the industry average at 51.29 times and the median at 37.02 times, indicating Dabo Medical's valuation is below the industry average but above the median [2]

Group 1 - The core viewpoint of the articles indicates that Dabo Medical's stock closed at 38.1 yuan, down 2.23%, with a rolling PE ratio of 39.62 times and a total market value of 15.774 billion yuan [1] - The average PE ratio for the medical device industry is 51.00 times, with a median of 37.03 times, placing Dabo Medical at the 80th position in the industry ranking [1][2] - As of the first quarter of 2025, 11 institutions hold shares in Dabo Medical, including 7 funds, with a total holding of 195.8747 million shares valued at 6.766 billion yuan [1] Group 2 - Dabo Medical specializes in the production, research, and sales of high-value medical consumables, with key products including intramedullary nails, hollow nails, and various orthopedic implants [1] - The latest financial report for the first quarter of 2025 shows that the company achieved an operating income of 550 million yuan, a year-on-year increase of 28.80%, and a net profit of 103 million yuan, a year-on-year increase of 67.04%, with a gross profit margin of 69.64% [1]

Company Overview - Dabo Medical's closing price on May 26 was 37.68 yuan, down 1.13%, with a rolling PE ratio of 39.18 times and a total market capitalization of 15.6 billion yuan [1] - The company ranks 81st in the medical device industry, which has an average PE ratio of 48.92 times and a median of 35.68 times [1][2] - Dabo Medical specializes in the production, research, and sales of high-value medical consumables, including a wide range of orthopedic products [1] Financial Performance - In the first quarter of 2025, Dabo Medical reported revenue of 550 million yuan, a year-on-year increase of 28.80%, and a net profit of 103 million yuan, up 67.04% year-on-year, with a gross profit margin of 69.64% [1] Capital Flow - On May 26, Dabo Medical experienced a net outflow of 7.68 million yuan in principal funds, with a total outflow of 16.74 million yuan over the past five days [1]

Group 1 - The core stock price of Dabo Medical (002901) closed at 38.11 yuan on May 23, 2025, reflecting a 0.4% increase from the previous week's closing price of 37.96 yuan [1] - The highest intraday price reached 39.09 yuan on May 19, 2025, while the lowest intraday price was 37.56 yuan on May 22, 2025 [1] - The current total market capitalization of Dabo Medical is 15.778 billion yuan, ranking 12th out of 126 in the medical device sector and 960th out of 5148 in the A-share market [1] Group 2 - Dabo Medical held its 2024 annual general meeting on May 21, 2025, with a total of 7 shareholders and representatives present, representing 347,095,811 shares, which is 83.8356% of the total shares [2] - An additional 87 shareholders participated via online voting, representing 3,634,395 shares, or 0.8778% of the total shares [2] - The meeting approved several resolutions, including the 2024 annual financial report and the proposal for the distribution of profits [2] Group 3 - The profit distribution plan for 2024 states that Dabo Medical will distribute a cash dividend of 5.00 yuan (including tax) for every 10 shares, totaling 203.304803 million yuan (including tax) [3] - The record date for the distribution of rights is set for May 29, 2025, and the ex-dividend date is May 30, 2025 [3] - No bonus shares will be issued, and there will be no capital reserve fund conversion into share capital [3]

证券代码：002901 证券简称：大博医疗 公告编号：2025-027 大博医疗科技股份有限公司 2024 年年度利润分配实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、大博医疗科技股份有限公司（以下简称"公司"）回购专用证券账户中 的股份 7,409,900 股不参与本次利润分配。公司 2024 年年度利润分配方案为：以 公司总股本 414,019,506 股扣除公司回购专用证券账户中的 7,409,900 股后的 406,609,606 股为基数，向全体股东每 10 股派发现金股利 5.00 元（含税），合计 派发现金红利 203,304,803.00 元（含税），不送红股，不以资本公积金转增股本。 如公司总股本在分配预案披露至实施期间因可转债转股、股份回购、股权激励行 权、再融资新增股份上市等原因而发生变化的，将按照分配比例不变的原则对分 配总额进行调整。 2、本次实施利润分配后，按公司总股本（含回购股份）折算每股现金分红 计算如下：按总股本折算每 10 股现金红利=现金分红总额÷公司总股本（含回购 股份）×10=203,304 ...

Core Viewpoint - The legal opinion letter issued by Fujian Xinshi Law Firm confirms that the 2024 Annual General Meeting of Dahua Medical Technology Co., Ltd. is convened and conducted in compliance with relevant laws and regulations, ensuring the legality and validity of the meeting and its resolutions [1][13]. Group 1: Meeting Procedures - The meeting is scheduled for May 21, 2025, and the notice was published on April 24, 2025, on the designated information disclosure website [3][4]. - The meeting will utilize both on-site and online voting platforms, with specific time slots for each voting method [3][4]. Group 2: Attendance and Voting - A total of 7 shareholders attended the meeting, representing 347,095,811 shares, which accounts for 83.8356% of the total shares [4]. - The voting results for various proposals were reported, with significant support from shareholders, including small investors [8][9][10][11][12]. Group 3: Resolutions Passed - The following proposals were approved during the meeting: - 2024 Annual Board Work Report: 350,566,792 shares in favor, representing 84.6740% [7]. - 2024 Annual Supervisory Board Work Report: 350,566,792 shares in favor, representing 84.6740% [9]. - 2024 Annual Financial Settlement Report: 350,565,792 shares in favor, representing 84.6737% [10]. - 2024 Profit Distribution Proposal: 350,720,906 shares in favor, representing 84.7112% [11]. - 2024 Annual Report: 350,566,292 shares in favor, representing 84.6739% [12]. - Appointment of 2025 Audit Firm: 350,411,006 shares in favor, representing 84.6364% [12]. - 2025 Executive Compensation Assessment Method: 350,722,306 shares in favor, representing 84.7115% [12].

证券代码：002901 证券简称：大博医疗 公告编号：2025-026 大博医疗科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议的召开和出席情况 （一）会议召开情况 1、会议召开的日期、时间： （1）现场会议召开时间：2025 年 5 月 21 日（星期三）下午 14:00 （2）网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 21 日 上午 9:15-9:25、9:30-11:30，下午 13:00-15:00。 ②通过深圳证券交易所互联网投票系统投票的开始时间为 2025 年 5 月 21 日 上午 9:15 至下午 15:00 期间的任意时间。 2、会议召开方式：本次股东大会采用现场表决与网络投票相结合的方式召 开。 3、会议召集人：公司董事会 4、会议主持人：公司董事长林志雄先生主持会议。 1 5、现场会议地点： 厦门市海沧区山边洪东路 18 号公司 ...

福建信实律师事务所 关于 大博医疗科技股份有限公司 2024 年年度股东大会 之 法 律 意 见 书 福建信实律师事务所 中国·厦门市思明区湖滨南路 334 号二轻大厦 9 层 电话/Tel：86 592 590 9988 传真/Fax：86 592 590 9989 www.lhxs.com 厦门湖滨南路 334 号二轻大厦 9 楼 邮编 361001 电话 +86 592 5909988 传真 +86 592-5909989 www.lhxs.com 福建信实律师事务所 关于大博医疗科技股份有限公司 2024 年年度股东大会之 法 律 意 见 书 (2025)闽信实律书字 0135 号 致：大博医疗科技股份有限公司 福建信实律师事务所(以下简称"本所")受大博医疗科技股份有限公司(以下 简称"公司")的委托，指派许智明律师、吴上烁律师 (以下简称"本所律师") 出席公司于2025年5月21日召开的公司2024年年度股东大会(以下简称"本次股东 大会")。本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以下 简称" ...

Core Viewpoint - Dabo Medical's stock closed at 38.44 yuan, down 2.04%, with a rolling PE ratio of 39.97 times and a total market value of 15.915 billion yuan [1] Company Summary - Dabo Medical Technology Co., Ltd. specializes in the production, research, and sales of high-value medical consumables, including intramedullary nails, hollow nails, ordinary plates, locking plates, and various orthopedic products [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 550 million yuan, a year-on-year increase of 28.80%, and a net profit of 103 million yuan, a year-on-year increase of 67.04%, with a gross profit margin of 69.64% [1] Shareholder Information - As of March 31, 2025, Dabo Medical had 18,310 shareholders, an increase of 374 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Summary - The average PE ratio for the medical device industry is 49.84 times, with a median of 36.59 times, placing Dabo Medical at the 81st position in the industry ranking [2] - The industry average market value is 105.51 billion yuan, while the median market value is 46.93 billion yuan [2]

Group 1: Industry Overview - The overall revenue growth rate for the pharmaceutical and biotechnology sector in Q1 2025 was -4.8%, with a net profit growth rate of -12.2%[3] - The raw material drug sector showed resilience with a revenue growth rate of -3.6% and a net profit growth rate of 10.5% in Q1 2025, benefiting from demand recovery and price stabilization[3] Group 2: Profitability and Financial Performance - In 2024, major raw material drug companies saw an increase in gross margin and net margin by 0.78 percentage points and 0.39 percentage points respectively, while Q1 2025 saw a decline in average gross margin and net margin by 0.64 percentage points and 1.87 percentage points respectively[5] - The average operating cash flow for major raw material drug companies reached 10.04 billion yuan in 2024, a 14.65% increase from 2023, indicating a positive trend[31] Group 3: Capital Expenditure Trends - Capital expenditure for major raw material drug companies in 2024 totaled 7.242 billion yuan, reflecting a year-over-year decrease of 4.12%[36] - The capital expenditure to depreciation ratio for the raw material drug sector decreased from 1.79 in 2023 to 1.27 in 2024, indicating ongoing capacity reduction and structural adjustments[36] Group 4: Investment Strategy - Investment recommendations focus on selecting raw material drug companies with strong growth attributes and stable competitive landscapes, particularly in bulk and specialty raw materials[44] - Companies like Guobang Pharmaceutical and Tianyu Co., Ltd. are highlighted for their favorable supply dynamics and demand recovery[44] Group 5: Risk Factors - Risks include intensified competition leading to suboptimal recovery in product prices and volumes, production safety incidents, and exchange rate fluctuations impacting profitability[47]